No, natural supplements cannot replace prescribed GLP-1 receptor agonists
That visibility matters even more when the medication itself has built-in variability
The FDA approved Wegovy, the first GLP-1 exclusively for weight loss, in 2021, and in the past five years, prescriptions for this class of drugs have more than quadrupled
It may be addressing an important gap in the market
What weve seen from the early returns in the obesity market is that it is heavily consumer-driven
Possible reasons include Type 1 diabetes diagnosis, advanced Type 2 diabetes with severely depleted beta cells, contraindication to GLP-1 drugs (thyroid cancer history, pancreatitis history), insurance or cost barriers, prior GLP-1 intolerance, or very high blood sugar requiring immediate insulin coverage